Ad agency nabs two new accounts, one from M&C Saatchi
bcg2 Healthcare has nabbed an account from M&C Saatchi without a pitch.
It’s scored the business for the launch of Avigra (pronounced “a-vee-gra”), the new brand for Pfizer’s little blue pill that’ll compete against a raft of expected generic brand competitors.
The launch is set for
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Yearly Premium Online Subscription
NZ$499.00 / yearly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Individual
Group membership
NBR Marketplace
Hazel Phillips
Tue, 03 May 2011
Tue, 03 May 2011
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Ad agency nabs two new accounts, one from M&C Saatchi
14280